{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"71","upperLimit":"85","value":"79"},{"groupId":"OG001","lowerLimit":"45","upperLimit":"81","value":"65"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9","upperLimit":"22","value":"15"},{"groupId":"OG001","lowerLimit":"4","upperLimit":"30","value":"13"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"6","value":"2"},{"groupId":"OG001","lowerLimit":"2","upperLimit":"26","value":"10"}]}],"title":"SD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"6","value":"2"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"17","value":"3"}]}],"title":"PD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"3","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"11","value":"0"}]}],"title":"NE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"8","value":"3"},{"groupId":"OG001","lowerLimit":"2","upperLimit":"26","value":"10"}]}],"title":"Not Done"}],"denoms":[{"counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"description":"BOR was defined as the percentage of participants with CR, PR, stable disease (SD), PD, NE (not evaluable) or not done as best response to treatment by the Lugano Classification. CR and PR are defined in OM#1. SD, PD and not done are defined in OM#6. Percentages were rounded off.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with r/r B-cell iNHL subtype of FL received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.","id":"OG000","title":"Axicabtagene Ciloleucel (Follicular Lymphoma)"},{"description":"Participants with r/r B-cell iNHL subtype of MZL received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.","id":"OG001","title":"Axicabtagene Ciloleucel (Marginal Zone Lymphoma)"}],"paramType":"NUMBER","populationDescription":"Participants in the Full Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 85.6 months","title":"Percentage of Participants With BOR Per the Lugano Classification by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}